2017
Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer
O’Connor M, Morrow MMB, Hunt KN, Boughey JC, Wahner-Roedler DL, Conners AL, Rhodes DJ, Hruska CB. Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer. EJNMMI Research 2017, 7: 5. PMID: 28091980, PMCID: PMC5237435, DOI: 10.1186/s13550-017-0255-6.Peer-Reviewed Original ResearchBreast cancerBenign lesionsMolecular subtypesBreast lesionsTumor molecular subtypeOverall diagnostic performancePathologic sizeAnalyzable patientsTumor extentMalignant tumorsLesion extentBlinded fashionLesion sizeSestamibiMolecular breastPatientsLesionsAlternative radiotracersLesion uptakeAssessment scoresROC analysisCancerInterest analysisDiagnostic performanceExamination one
2012
The Use of Molecular Breast Imaging to Assess Response in Women Undergoing Neoadjuvant Therapy for Breast Cancer
Wahner-Roedler DL, Boughey JC, Hruska CB, Chen B, Rhodes DJ, Tortorelli CL, Maxwell RW, S. S, O'Connor MK. The Use of Molecular Breast Imaging to Assess Response in Women Undergoing Neoadjuvant Therapy for Breast Cancer. Clinical Nuclear Medicine 2012, 37: 344-350. PMID: 22391702, PMCID: PMC3296091, DOI: 10.1097/rlu.0b013e31824437b3.Peer-Reviewed Original ResearchConceptsMolecular breast imagingNeoadjuvant therapyTumor sizeBreast cancerResidual tumor sizeProspective pilot studyInvasive breast cancerBreast cancer treatmentTumor-specific radiopharmaceuticalsPathologic extentResidual diseasePretreatment valuesTumor responseTumor extentPosttreatment valuesIntravenous injectionPathologic measurementsRadiotracer uptakePredictive valueMolecular breastPatientsCancerCancer treatmentPilot studyInterest analysis